A non-selective mACh receptor antagonist and non-specific inhibitor of voltage-gated ion channels in neurons used to study animal models of vertigo and emesis.
A non-selective mACh receptor antagonist and non-specific inhibitor of voltage-gated ion channels in neurons used to study animal models of vertigo and emesis.
A selective, reversible inhibitor of MAO-B (Ki = 0.091 &muM) over MAO-A (Ki = 9.06 &muM) may ameliorate depression, Parkinson&rsquos disease, Alzheimer&rsquos disease, Huntington&rsquos disease, and stroke.
A selective, reversible inhibitor of MAO-B (Ki = 0.091 &muM) over MAO-A (Ki = 9.06 &muM) may ameliorate depression, Parkinson&rsquos disease, Alzheimer&rsquos disease, Huntington&rsquos disease, and stroke.
A competitive antagonist of muscarinic receptors that potently blocks signaling through M1, M2, and M3 (Kis = 25, 125, and 10 nM, respectively), resulting in muscle relaxation.
A competitive antagonist of muscarinic receptors that potently blocks signaling through M1, M2, and M3 (Kis = 25, 125, and 10 nM, respectively), resulting in muscle relaxation.
An anti-epileptic drug that inhibits the synaptosomal uptake of GABA, increasing the activation of GABAA receptors inhibits CYP3A4, CYP1A2, and CYP2C19 inhibits LDH, blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human
An anti-epileptic drug that inhibits the synaptosomal uptake of GABA, increasing the activation of GABAA receptors inhibits CYP3A4, CYP1A2, and CYP2C19 inhibits LDH, blocking both lactate-to-pyruvate and pyruvate-to-lactate conversions by human
A potassium channel activator that causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions relaxes rat aorta rings (ED<sub>50</sub> = 19.3 &muM) and has been used as a vasodilator in the treatment of
A potassium channel activator that causes local relaxation in smooth muscle by increasing membrane permeability to potassium ions relaxes rat aorta rings (ED<sub>50</sub> = 19.3 &muM) and has been used as a vasodilator in the treatment of
A selective, reversible inhibitor of MAO-B (Ki = 0.091 &muM) over MAO-A (Ki = 9.06 &muM) may ameliorate depression, Parkinson&rsquos disease, Alzheimer&rsquos disease, Huntington&rsquos disease, and stroke.
A selective, reversible inhibitor of MAO-B (Ki = 0.091 &muM) over MAO-A (Ki = 9.06 &muM) may ameliorate depression, Parkinson&rsquos disease, Alzheimer&rsquos disease, Huntington&rsquos disease, and stroke.
A competitive antagonist of muscarinic receptors that potently blocks signaling through M1, M2, and M3 (Kis = 25, 125, and 10 nM, respectively), resulting in muscle relaxation.
A competitive antagonist of muscarinic receptors that potently blocks signaling through M1, M2, and M3 (Kis = 25, 125, and 10 nM, respectively), resulting in muscle relaxation.
A selective L-type calcium channel blocker with long-acting antihypertensive activity relaxes depolarization-induced contractions of rabbit aorta (EC<sub>50</sub> = 1.4 nM) and reduces the rate of spontaneously beating guinea pig right atria
A selective L-type calcium channel blocker with long-acting antihypertensive activity relaxes depolarization-induced contractions of rabbit aorta (EC<sub>50</sub> = 1.4 nM) and reduces the rate of spontaneously beating guinea pig right atria